Aflibercept IVT

Preclinical

Aflibercept IVT is one of 2 therapeutic programs targeting Neovascular (Wet) Age-Related Macular Degeneration. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Neovascular (wet) Age-Related Macular DegenerationRecruiting

Neovascular (wet) Age-Related Macular DegenerationPreclinical

Recruiting

Competition

Competitive Landscape

3 competitors in Neovascular (wet) Age-Related Macular Degeneration

#DrugCompanyPhaseTrials

4d-150 Ivt

44D Molecular Therapeutics

Preclinical

1 2

Aflibercept IVT

44D Molecular Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 2Active, not recruiting

Diabetic Macular Edema

NCT05930561

Q1 2031

PreclinicalRecruiting

Neovascular (wet) Age-Related Macular Degeneration

NCT05197270

Clinical

Trials by Indication[1]

Neovascular (Wet) Age-Related Macular Degeneration1 trial

A Phase 1/2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults With Neovascular (Wet) Age-Related Macular Degeneration

Recruiting·44D Molecular Therapeutics·Preclinical·NCT05197270·215 enrolled

Diabetic Macular Edema1 trial

A Phase 2 Randomized, Active-Controlled, Double-masked Trial of Intravitreal 4D-150 Gene Therapy in Adults With Diabetic Macular Edema (SPECTRA)

Active, not recruiting·44D Molecular Therapeutics·Phase 2·NCT05930561·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Aflibercept IVT. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Aflibercept IVT. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — 4D Molecular Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: 44D Molecular Therapeutics

Aflibercept IVT

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2029

Q1 2031

Trials by Indication[1]

Neovascular (Wet) Age-Related Macular Degeneration1 trial

Diabetic Macular Edema1 trial

References

Drug Info

Quick Facts

Related News